The identification and advancement of small-molecule inhibitors aimed at the EGFR have significantly transformed the therapeutic paradigm across multiple cancer types, notably within non-small-cell lung cancer (NSCLC) [8,9,10]. Here, EGFR is linked to non-small cell lung carcinoma.